Cryoport, Inc.
CYRXIndustrialsNASDAQIntegrated Freight & Logistics
Scan Results
Daily timeframeCryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. With a market capitalization of $706.6M, it sits in small-cap territory. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry.
Market Cap
$706.6M
Beta
1.75
P/E (TTM)
—
P/E (Fwd)
-22.61
EPS (TTM)
$-0.90
EPS (Fwd)
$-0.62
ROE
-8.2%
ROA
-2.5%
Cash
$403.6M
Total Debt
$230.5M
Free CF
$64.5M
52W Change
135.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $403.6M in cash comfortably exceeding the $230.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $64.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -8.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $237.3M (2022) to $176.2M (2025), a 26% decline worth watching.
A beta of 1.75 means CYRX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CYRX.